Cargando…
Integrating public preferences into national reimbursement decisions: a descriptive comparison of approaches in Belgium and New Zealand
BACKGROUND: Public health care payer organizations face increasing pressures to make transparent and sustainable coverage decisions about ever more expensive prescription drugs, suggesting a need for public engagement in coverage decisions. However, little is known about countries’ approaches to int...
Autores principales: | Leopold, Christine, Lu, Christine Y., Wagner, Anita K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183657/ https://www.ncbi.nlm.nih.gov/pubmed/32334579 http://dx.doi.org/10.1186/s12913-020-05152-2 |
Ejemplares similares
-
Reimbursement of orphan drugs in Belgium: what (else) matters?
por: Picavet, Eline, et al.
Publicado: (2014) -
Impact of changing reimbursement criteria on the use of fluoroquinolones in Belgium
por: Vermeulen, Helene, et al.
Publicado: (2021) -
Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey
por: Polisena, Julie, et al.
Publicado: (2017) -
Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up
por: Litzroth, Amber, et al.
Publicado: (2019) -
The evolution of Taiwan’s National Health Insurance drug reimbursement scheme
por: Hsu, Jason C, et al.
Publicado: (2015)